 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | MDK-703 / Medikine
Journal: A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy. (Pubmed Central) - Oct 30, 2023
The novel peptide agonist reported here scores very low in predicted immunogenicity, and because the peptide lacks sequence similarity with IL-7, the problematic immunogenic neutralization of endogenous cytokine should not occur. The properties we report here implicate MDK-703 as a candidate for clinical evaluation in oncology, anti-viral and other infectious disease, vaccine enhancement, and treatment of lymphopenia.
- || MDK-703 / Medikine
Trial completion: A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers (clinicaltrials.gov) - Feb 15, 2023
P1, N=26, Completed, Sponsor: Medikine, Inc.
The properties we report here implicate MDK-703 as a candidate for clinical evaluation in oncology, anti-viral and other infectious disease, vaccine enhancement, and treatment of lymphopenia. Recruiting --> Completed
- |||| MDK-703 / Medikine
New P1/2 trial, Combination therapy, Monotherapy, Metastases: ORCHID-1: A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=150, Recruiting, Sponsor: Medikine, Inc.
- MDK-703 / Medikine
A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_949;
P1
Results As of July 28, 2022, the first cohort of subjects has been dosed. It is expected that preliminary data for three ascending dose cohorts will be available in November 2022 (Clinical trial information: NCT05366634 )
- || MDK-703 / Medikine
Enrollment open: A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers (clinicaltrials.gov) - Jul 25, 2022
P1, N=30, Recruiting, Sponsor: Medikine, Inc.
It is expected that preliminary data for three ascending dose cohorts will be available in November 2022 (Clinical trial information: NCT05366634 ) Not yet recruiting --> Recruiting
- | MDK-703 / Medikine
New P1 trial: A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers (clinicaltrials.gov) - May 8, 2022
P1, N=30, Not yet recruiting, Sponsor: Medikine, Inc.
- MDK-703 / Medikine
In vitro and in vivo properties of MDK703: An Fc-peptide fusion IL-7Rαγc agonist unrelated in structure to IL-7 (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_4154;
The structural novelty of MDK-703 eliminates the risk of ADAs that neutralize endogenous IL-7. A first human trial of MDK703 is anticipated in 2022.